Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study

Prognostic Factors of Uterine Serous Carcinoma—A Multicenter Study

“…Rauh-Hain et al 32 recommended that patients with stages IIICYIV USC should consist of maximal surgical cytoreduction followed by platinum-based chemotherapy, preferably in combination with paclitaxel. Mahdi et al 33 suggested that adjuvant vaginal brachytherapy significantly reduced the risk of vaginal recurrence in stage I noninvasive USC. It seems advisable to treat patients with USC with a combination of platinum-based chemotherapy and radiotherapy.…”

Omental Biopsy for Surgical Staging of Uterine Serous Carcinoma

“…2,21 Radiotherapy has been associated with better local control, especially in early stage disease, but no difference was noted in OS. 43,44 The high frequency of extrapelvic recurrences led to increased use of systemic adjuvant treatment with chemotherapy. Patients treated with chemotherapy have fewer recurrences and better survival rates than those who receive radiotherapy alone or are observed even in stage I.…”

The role of vaginal brachytherapy in stage I endometrial serous cancer: a systematic review

“…All studies were retrospective [19,20,21,22,23,24,25,26,27]. In accordance with the selection criteria, only data from the VBT treatment arms were extracted and considered for the analysis.…”

“…Many studies have reported significant toxicity rates in stage IA patients treated with chemotherapy and pelvic EBRT, with a DFS remaining at around 85% [38,39,40]. While some centers have adopted VBT as the local therapy in this setting [23,41,42], many centers continue to use pelvic EBRT as a standard treatment [43,44]. In well selected stage I USC, VBT may be particularly useful in reducing local recurrences and toxicity.…”